Canaccord lowered the firm’s price target on Perrigo to $42 from $49 and keeps a Buy rating on the shares. The firm said they remain buyers as they believe the company will get back on track once past the nutrition issues.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PRGO:
